Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
- Previous Close
0.3908 - Open
0.4000 - Bid 0.2800 x 200
- Ask 0.5275 x 200
- Day's Range
0.3923 - 0.4116 - 52 Week Range
0.3500 - 2.7500 - Volume
10,990 - Avg. Volume
75,027 - Market Cap (intraday)
6.782M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.
www.shuttlepharma.com8
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SHPH
Performance Overview: SHPH
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SHPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SHPH
Valuation Measures
Market Cap
6.78M
Enterprise Value
2.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.67
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.59
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-50.43%
Return on Equity (ttm)
-112.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.59M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
5.46M
Total Debt/Equity (mrq)
26.82%
Levered Free Cash Flow (ttm)
-2.75M
Research Analysis: SHPH
Analyst Price Targets
No Analyst Price Targets available for this ticker